AU2087501A - Amphiphilic polymers and polypeptide conjugates comprising same - Google Patents

Amphiphilic polymers and polypeptide conjugates comprising same Download PDF

Info

Publication number
AU2087501A
AU2087501A AU20875/01A AU2087501A AU2087501A AU 2087501 A AU2087501 A AU 2087501A AU 20875/01 A AU20875/01 A AU 20875/01A AU 2087501 A AU2087501 A AU 2087501A AU 2087501 A AU2087501 A AU 2087501A
Authority
AU
Australia
Prior art keywords
lcrf
moiety
polymer
peptide
polyethylene glycol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU20875/01A
Other languages
English (en)
Inventor
Nnochiri N. Ekwuribe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nobex Corp
Original Assignee
Nobex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nobex Corp filed Critical Nobex Corp
Publication of AU2087501A publication Critical patent/AU2087501A/en
Priority to AU2006200906A priority Critical patent/AU2006200906A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AU20875/01A 1999-12-13 2000-12-11 Amphiphilic polymers and polypeptide conjugates comprising same Abandoned AU2087501A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2006200906A AU2006200906A1 (en) 1999-12-13 2006-03-02 Amphiphilic polymers and polypeptide conjugates comprising same

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09459443 1999-12-13
US09/459,443 US6638906B1 (en) 1999-12-13 1999-12-13 Amphiphilic polymers and polypeptide conjugates comprising same
PCT/US2000/033592 WO2001041812A2 (en) 1999-12-13 2000-12-11 Amphiphilic polymers and polypeptide conjugates comprising same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2006200906A Division AU2006200906A1 (en) 1999-12-13 2006-03-02 Amphiphilic polymers and polypeptide conjugates comprising same

Publications (1)

Publication Number Publication Date
AU2087501A true AU2087501A (en) 2001-06-18

Family

ID=23824795

Family Applications (1)

Application Number Title Priority Date Filing Date
AU20875/01A Abandoned AU2087501A (en) 1999-12-13 2000-12-11 Amphiphilic polymers and polypeptide conjugates comprising same

Country Status (18)

Country Link
US (2) US6638906B1 (US06638906-20031028-C00029.png)
EP (1) EP1237580A2 (US06638906-20031028-C00029.png)
JP (1) JP2003516366A (US06638906-20031028-C00029.png)
KR (1) KR20020068053A (US06638906-20031028-C00029.png)
CN (1) CN1434725A (US06638906-20031028-C00029.png)
AU (1) AU2087501A (US06638906-20031028-C00029.png)
BR (1) BR0016339A (US06638906-20031028-C00029.png)
CA (1) CA2394928A1 (US06638906-20031028-C00029.png)
CZ (1) CZ20021990A3 (US06638906-20031028-C00029.png)
HK (1) HK1049283A1 (US06638906-20031028-C00029.png)
HU (1) HUP0300133A2 (US06638906-20031028-C00029.png)
IL (1) IL150119A0 (US06638906-20031028-C00029.png)
MX (1) MXPA02005885A (US06638906-20031028-C00029.png)
NO (1) NO20022793L (US06638906-20031028-C00029.png)
PL (1) PL359174A1 (US06638906-20031028-C00029.png)
RU (1) RU2002118709A (US06638906-20031028-C00029.png)
WO (1) WO2001041812A2 (US06638906-20031028-C00029.png)
ZA (1) ZA200204603B (US06638906-20031028-C00029.png)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9425138D0 (en) 1994-12-12 1995-02-08 Dynal As Isolation of nucleic acid
US6703381B1 (en) * 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
US20090281023A9 (en) * 2001-06-04 2009-11-12 Nobex Corporation Mixtures Of Calcitonin Drug-Oligomer Conjugates And Methods Of Use In Pain Treatment
US6828305B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
EP1468116A2 (en) 2002-01-16 2004-10-20 Dynal Biotech ASA Method for isolating nucleic acids and protein from a single sample
US20040062748A1 (en) * 2002-09-30 2004-04-01 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US8129330B2 (en) 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US7648962B2 (en) * 2002-11-26 2010-01-19 Biocon Limited Natriuretic compounds, conjugates, and uses thereof
EP1569683B1 (en) * 2002-11-26 2010-03-03 Biocon Limited Modified natriuretic compounds, conjugates, and uses thereof
GB0229287D0 (en) * 2002-12-16 2003-01-22 Dna Res Innovations Ltd Polyfunctional reagents
CN1761680A (zh) 2002-12-26 2006-04-19 武田药品工业株式会社 肿瘤迁移抑制素衍生物及其用途
US7553930B2 (en) 2003-01-06 2009-06-30 Xencor, Inc. BAFF variants and methods thereof
CA2544156C (en) * 2003-10-29 2012-07-10 Altus Pharmaceuticals Inc. Non-pancreatic proteases for controlling plasma cholecystokinin (cck) concentration and for treating pain
AU2005257484A1 (en) 2004-06-25 2006-01-05 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
US8329958B2 (en) 2004-07-02 2012-12-11 Biocon Limited Combinatorial synthesis of PEG oligomer libraries
US8168222B2 (en) * 2004-09-07 2012-05-01 Board Of Regents Of The University Of Nebraska Amphiphilic polymer-protein conjugates and methods of use thereof
WO2006076471A2 (en) * 2005-01-12 2006-07-20 Nobex Corporation Bnp conjugates and methods of use
CA2606270A1 (en) * 2005-04-19 2006-10-26 Massachusetts Institute Of Technology Amphiphilic polymers and methods of use thereof
US20070026383A1 (en) * 2005-07-15 2007-02-01 Quintessence Biosciences, Inc. Methods and compositions for extracting membrane proteins
US8404643B2 (en) 2005-12-22 2013-03-26 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
TWI404726B (zh) 2006-10-25 2013-08-11 Takeda Pharmaceutical 腫瘤轉移抑制素衍生物及其用途
PT2314609T (pt) * 2008-07-30 2017-03-06 Takeda Pharmaceuticals Co Derivado de metastina e sua utilização
MX2013009859A (es) 2011-03-01 2014-02-28 Novo Nordisk As Ligandos dr3 antagonicos.
CN103740659B (zh) * 2012-05-10 2015-06-03 江南大学 一种提高酶热稳定性的方法
CN103740661B (zh) * 2012-05-10 2015-06-03 江南大学 一种提高酶热稳定性的方法
US20140039158A1 (en) * 2012-07-25 2014-02-06 Belrose Pharma, Inc. Polymeric conjugates and methods of preparing the same
CN106729735B (zh) * 2017-03-09 2020-05-12 国家纳米科学中心 一种pH敏感的多肽聚合物及其制备方法和应用
BR112020021134A2 (pt) * 2018-04-16 2021-03-23 Merck Patent Gmbh aditivos para formulações de proteínas para aprimorar estabilidade térmica
KR20240026573A (ko) * 2022-08-22 2024-02-29 부산대학교 산학협력단 폴리소르베이트-숙신산-카르니틴 복합체 및 이를 포함하는 생리활성 물질 또는 약물 전달용 조성물

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5411947A (en) 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US5407683A (en) 1990-06-01 1995-04-18 Research Corporation Technologies, Inc. Pharmaceutical solutions and emulsions containing taxol
IE912365A1 (en) * 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
WO1994005282A1 (en) 1992-09-04 1994-03-17 The Scripps Research Institute Water soluble taxol derivatives
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US6191105B1 (en) 1993-05-10 2001-02-20 Protein Delivery, Inc. Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
US5681811A (en) * 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US5359030A (en) * 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
EP0862631A1 (en) 1995-10-26 1998-09-09 The Board Of Regents, The University Of Texas System Luminal cholecystokinin-releasing factor
JP3737518B2 (ja) 1996-03-12 2006-01-18 ピージー−ティーエックスエル カンパニー， エル．ピー． 水溶性パクリタキセルプロドラッグ
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
IL133585A0 (en) 1997-06-20 2001-04-30 Baker Norton Pharma Soluble prodrugs of paclitaxel
US6495514B1 (en) * 1998-01-21 2002-12-17 Mercer University Method for reducing inflammation and inducing an analgesic effect and compounds thereof
US6309633B1 (en) 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
KR100345214B1 (ko) * 1999-08-17 2002-07-25 이강춘 생체적합성 고분자가 수식된 펩타이드의 비점막 전달
US6713452B2 (en) * 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same

Also Published As

Publication number Publication date
CN1434725A (zh) 2003-08-06
RU2002118709A (ru) 2004-02-27
HK1049283A1 (zh) 2003-05-09
KR20020068053A (ko) 2002-08-24
BR0016339A (pt) 2002-08-27
NO20022793D0 (no) 2002-06-12
WO2001041812A3 (en) 2002-03-21
CZ20021990A3 (cs) 2002-11-13
US20040092449A1 (en) 2004-05-13
IL150119A0 (en) 2002-12-01
JP2003516366A (ja) 2003-05-13
EP1237580A2 (en) 2002-09-11
NO20022793L (no) 2002-08-13
PL359174A1 (en) 2004-08-23
CA2394928A1 (en) 2001-06-14
HUP0300133A2 (en) 2003-05-28
ZA200204603B (en) 2003-11-26
US6638906B1 (en) 2003-10-28
MXPA02005885A (es) 2002-10-23
WO2001041812A2 (en) 2001-06-14

Similar Documents

Publication Publication Date Title
US6638906B1 (en) Amphiphilic polymers and polypeptide conjugates comprising same
AU698944B2 (en) Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations
AU694919B2 (en) Conjugation-stabilized polypeptide compositions
US20170189544A1 (en) Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
CA2500389C (en) Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US6191105B1 (en) Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
RU2139732C1 (ru) Амплификация системы поглощения витамина b12 при помощи полимеров
KR20140040164A (ko) 인슐린 저항성에 대한 개선된 펩티드 제약
US20020099001A1 (en) Oral delivery of chemically modified proteins
JP2022058911A (ja) 非血液凝固タンパク質の糖ポリシアル酸化
TW200418451A (en) Modified carbamate-containing prodrugs and methods of synthesizing same
AU2006200906A1 (en) Amphiphilic polymers and polypeptide conjugates comprising same
KR100695587B1 (ko) 부갑상성 호르몬과 생체적합성 고분자의 1:1 접합체,이의 제조방법과 이를 함유하는 약학 조성물
ZA200502707B (en) Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof